OUR
PIPELINE

OUR
PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAMPhase Phase 11 Phase 22 Phase 33
BRENTUXIMAB VEDOTIN1
 
CD30 Antibody Drug Conjugate

Hodgkin Lymphoma,
Peripheral T-Cell Lymphoma

BRIGATINIB
 
ALK Inhibitor

Non-small Cell Lung Cancer

IXAZOMIB
 
Proteasome Inhibitor

Multiple Myeloma,
Amyloidosis

PEVONEDISTAT
 
Nedd8-Activating Enzyme Inhibitor

Higher-Risk Myelodysplastic Syndromes,
Chronic Myelomonocytic Leukemia,
Low-Blast Acute Myelogenous Leukemia

 
Nedd8-Activating Enzyme Inhibitor

Solid Tumors

PONATINIB2
 
BCR-ABL Inhibitor

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia

VEDOLIZUMAB
 
Anti-α4β7 Antibody

Graft versus Host Disease

SAPANISERTIB (TAK-228)
 
TORC1/TORC2 Inhibitor

Endometrial Cancer

 
TORC1/TORC2 Inhibitor

Solid Tumors

TAK-659
 
SYK/FLT-3 Inhibitor

Lymphoma

TAK-931
 
CDC7 Inhibitor

Esophageal Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer

 
CDC7 Inhibitor

Solid Tumors

CABOZANTINIB3
 
MET, VEGF, AXL and RET Inhibitor

Renal Cell Carcinoma, Hepatocellular Carcinoma

ALISERTIB
 
Aurora A Inhibitor

Acute Myeloid Leukemia

NIRAPARIB4
 
PARP Inhibitor

Ovarian Cancer

TAK-788
 
EGFR/HER2 Inhibitor

Non-small Cell Lung Cancer

TAK-573
 
CD38-targeted IgG4 fused with attenuated IFNα

Multiple Myeloma

TAK-164
 
Anti-guanylyl cyclase C antibody drug conjugate

Gastrointestinal Cancers

TAK-079
 
Anti-CD38 antibody

Multiple Myeloma

TAK-252/SL-2792525
 
Agonist Redirected Checkpoint Fusion Protein PD1/OX40L

Solid Tumors

TAK-981
 
SUMO activating Enzyme inhibitor

Solid Tumors

Last updated 2019-05
All programs have Global Development Rights unless otherwise noted.

  1. Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc.
  2. Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories).
  3. Japan Only.
  4. Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.
  5. Takeda retains an option to develop TAK-252/SL-279252 with Shattuck Labs.